QGEN

Qiagen N.V. NYSE

Healthcare ·Medical - Diagnostics & Research ·NL · qiagen.com

$33.96

After hrs $34.00 +0.00%

Mkt Cap $7.0B

52w Low $33.17 3.2% of range 52w High $57.82

50d MA $41.64 200d MA $46.23

P/E (TTM) 16.8x

EV/EBITDA 14.9x

P/B 1.9x

Debt/Equity 0.4x

ROE 11.2%

P/FCF 21.7x

RSI (14) —

ATR (14) —

Beta 0.79

50d MA $41.64

200d MA $46.23

Avg Volume 2.0M

About

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic … QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 4, 2026	AMC	0.61	0.62	+1.6%	51.71	-3.5%	-0.9%	-1.5%	-1.8%	-1.2%	-1.3%	—
Nov 4, 2025	AMC	0.61	0.64	+4.9%	44.16	-1.7%	-0.2%	-2.5%	-1.4%	-2.2%	+0.1%	—
Aug 5, 2025	AMC	0.60	0.60	+0.0%	49.95	-0.4%	-4.9%	-3.2%	-3.8%	-3.9%	-2.0%	—
May 7, 2025	AMC	0.50	0.55	+9.3%	42.63	-0.1%	-1.1%	-1.8%	+0.8%	-1.2%	-3.5%	—
Feb 5, 2025	AMC	0.60	0.61	+1.7%	43.80	-3.9%	-3.1%	-5.6%	-8.5%	-10.3%	-8.4%	—
Nov 6, 2024	AMC	0.54	0.57	+5.6%	42.86	+3.0%	+0.7%	-0.2%	+0.4%	-1.4%	-2.8%	—
Jul 31, 2024	AMC	0.53	0.57	+7.5%	43.47	+0.6%	+2.9%	+4.0%	+0.9%	+0.5%	-0.1%	—
Apr 29, 2024	AMC	0.44	0.46	+4.5%	41.33	-1.9%	+0.1%	+1.2%	+0.9%	+1.6%	+0.7%	—
Feb 6, 2024	AMC	0.55	0.55	+0.0%	43.78	-1.3%	-2.9%	-1.5%	-0.7%	-2.2%	-4.3%	—
Oct 30, 2023	AMC	0.52	0.53	+1.9%	35.82	+2.5%	+5.3%	+6.5%	+7.4%	+10.2%	+9.5%	—
Aug 8, 2023	AMC	0.53	0.54	+1.9%	44.93	+2.7%	+0.3%	-0.6%	-1.9%	-1.1%	-1.7%	—
May 3, 2023	AMC	0.50	0.54	+8.0%	45.27	+3.4%	+2.5%	+2.3%	+2.5%	+0.2%	+1.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 29	Baird	Upgrade	Neutral → Outperform	$43	$34.02	$33.62	-1.2%	-1.2%	+1.6%	+0.7%	—	—
Apr 14	Barclays	Downgrade	Overweight → Equal Weight	—	$41.91	$41.89	-0.0%	-0.4%	-0.6%	-2.3%	-1.6%	-2.1%
Mar 13	Deutsche Bank	Upgrade	Hold → Buy	—	$41.12	$41.83	+1.7%	-1.3%	-0.5%	+1.0%	-1.6%	-1.1%
Feb 6	Stifel	Maintains	Hold → Hold	—	$51.23	$51.25	+0.0%	-0.5%	-0.9%	-0.3%	-0.3%	-0.7%
Feb 6	JP Morgan	Maintains	Overweight → Overweight	—	$51.23	$51.25	+0.0%	-0.5%	-0.9%	-0.3%	-0.3%	-0.7%
Feb 6	Citigroup	Maintains	Neutral → Neutral	—	$51.23	$51.25	+0.0%	-0.5%	-0.9%	-0.3%	-0.3%	-0.7%
Jan 22	Deutsche Bank	Downgrade	Buy → Hold	—	$55.66	$54.72	-1.7%	-2.5%	-0.1%	-2.6%	-2.6%	-3.0%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$45.22	$47.92	+6.0%	+5.8%	+4.8%	+5.2%	+4.7%	+6.1%
Dec 11	Citigroup	Downgrade	Buy → Neutral	—	$45.66	$45.59	-0.2%	-0.5%	-1.0%	+4.8%	+3.8%	+4.2%
Oct 2	Barclays	Maintains	Overweight → Overweight	—	$46.32	$46.30	-0.0%	-0.2%	+1.0%	+1.4%	+1.0%	+3.1%
Aug 7	UBS	Maintains	Neutral → Neutral	—	$47.49	$47.93	+0.9%	+1.8%	+1.2%	+1.1%	+3.1%	+3.7%
Jun 26	BofA Securities	Maintains	Buy → Buy	—	$47.45	$48.30	+1.8%	+1.2%	+0.7%	+1.3%	+1.6%	+2.5%
Apr 21	Baird	Maintains	Neutral → Neutral	—	$40.71	$40.61	-0.2%	-0.6%	+4.0%	+4.0%	+5.8%	+3.3%
Apr 4	Redburn Atlantic	Downgrade	Buy → Neutral	—	$40.37	$39.61	-1.9%	-5.2%	-0.1%	-3.9%	+2.6%	-0.8%
Feb 19	Baird	Downgrade	Outperform → Neutral	—	$40.01	$39.36	-1.6%	-2.0%	-3.6%	-1.1%	-0.2%	-0.8%
Feb 7	UBS	Maintains	Neutral → Neutral	—	$42.44	$41.38	-2.5%	-2.6%	-5.6%	-7.4%	-5.4%	-5.6%
Jan 6	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$43.94	$43.55	-0.9%	-0.4%	-0.1%	+0.6%	-0.6%	+2.3%
Dec 10	Jefferies	Upgrade	Hold → Buy	—	$43.31	$45.10	+4.1%	+3.9%	+4.2%	+3.7%	+2.4%	+2.4%
Feb 8	JP Morgan	Maintains	Overweight → Overweight	—	$42.52	$42.74	+0.5%	+1.4%	+2.2%	+0.7%	-1.5%	-1.5%
Feb 8	Citigroup	Maintains	Buy → Buy	—	$42.52	$42.74	+0.5%	+1.4%	+2.2%	+0.7%	-1.5%	-1.5%
Dec 20	JP Morgan	Maintains	Overweight → Overweight	—	$43.28	$43.20	-0.2%	-2.2%	+0.3%	+0.5%	+1.2%	+1.2%
Dec 7	Goldman Sachs	Upgrade	Neutral → Buy	—	$41.74	$42.20	+1.1%	+1.4%	+0.8%	+1.6%	+1.1%	+4.0%
Nov 2	UBS	Maintains	Neutral → Neutral	—	$38.15	$38.45	+0.8%	+0.9%	+3.5%	+2.8%	+3.6%	+2.4%
Oct 16	JP Morgan	Maintains	Overweight → Overweight	—	$38.74	$38.82	+0.2%	+1.8%	+1.2%	-1.6%	-2.4%	-2.4%
Sep 25	Citigroup	Maintains	Buy → Buy	—	$39.71	$39.39	-0.8%	-0.7%	+0.5%	+0.1%	+0.7%	+2.7%
Aug 8	UBS	Maintains	Neutral → Neutral	—	$45.55	$45.39	-0.4%	-1.4%	-1.1%	-1.9%	-3.3%	-2.5%
Feb 8	UBS	Maintains	Neutral → Neutral	—	$50.17	$51.02	+1.7%	-0.9%	-1.3%	-1.2%	-1.9%	-2.1%
Feb 8	Citigroup	Maintains	Buy → Buy	—	$50.17	$51.02	+1.7%	-0.9%	-1.3%	-1.2%	-1.9%	-2.1%
Nov 8	Citigroup	Maintains	Buy → Buy	—	$42.24	$43.97	+4.1%	+5.6%	+6.1%	+11.4%	+14.9%	+12.5%
Dec 13	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$54.75	$54.76	+0.0%	+0.8%	-0.4%	+2.9%	+1.8%	+1.3%
Oct 14	Redburn Partners	Maintains	Buy → Buy	—	$51.68	$52.26	+1.1%	+1.0%	+0.7%	+1.6%	+2.5%	+3.7%
Jul 13	Kepler Cheuvreux	Downgrade	Buy → Hold	—	$49.15	$47.48	-3.4%	-3.4%	-4.6%	-1.8%	-3.1%	-0.3%
Jun 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$47.40	$46.77	-1.3%	-0.9%	-1.0%	+0.2%	-0.1%	-0.3%
Oct 5	BofA Securities	Upgrade	Neutral → Buy	—	$52.71	$53.06	+0.7%	+1.7%	+3.7%	+3.9%	+3.3%	+4.6%
Sep 27	Kepler Cheuvreux	Upgrade	Hold → Buy	—	—	—	—	—	—	—	—	—
Aug 25	Commerzbank	Upgrade	Hold → Buy	—	$52.00	$51.53	-0.9%	+0.3%	+0.8%	-2.6%	-1.9%	-1.3%
Aug 23	Citigroup	Upgrade	Neutral → Buy	—	—	—	—	—	—	—	—	—
Aug 20	JP Morgan	Maintains	Overweight → Overweight	—	$52.81	$52.44	-0.7%	-2.2%	-0.1%	-1.5%	-1.2%	-0.7%
Aug 13	Deutsche Bank	Upgrade	Hold → Buy	—	$48.77	$49.37	+1.2%	+0.5%	+2.2%	+6.1%	+7.8%	+8.3%
Aug 13	Exane BNP Paribas	Upgrade	Neutral → Outperform	—	$48.77	$49.37	+1.2%	+0.5%	+2.2%	+6.1%	+7.8%	+8.3%
Apr 1	Stifel	Maintains	Hold → Hold	—	$41.90	$40.59	-3.1%	-3.3%	-3.6%	-3.2%	-3.8%	-3.3%
Mar 5	CFRA	Maintains	Hold → Hold	—	$41.80	$41.94	+0.3%	+0.1%	+0.2%	-0.4%	-0.1%	-1.0%
Feb 5	CFRA	Maintains	Hold → Hold	—	$33.41	$36.22	+8.4%	+5.1%	+7.8%	+7.0%	+7.8%	+8.5%
Jan 9	UBS	Maintains	Neutral → Neutral	—	$33.92	$34.22	+0.9%	+2.9%	+2.7%	+4.3%	+5.0%	+0.9%
Jan 8	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$33.53	$33.44	-0.3%	+1.2%	+4.1%	+3.9%	+5.5%	+6.2%
Jan 7	Citigroup	Maintains	Neutral → Neutral	—	$33.73	$33.49	-0.7%	-0.6%	+0.6%	+3.5%	+3.3%	+4.9%
Nov 17	Commerzbank	Upgrade	Hold → Buy	—	—	—	—	—	—	—	—	—
Nov 15	Stifel Nicolaus	Maintains	Hold → Hold	—	$37.55	$37.96	+1.1%	+8.8%	+10.1%	+10.1%	+9.4%	+10.0%
Nov 13	JP Morgan	Upgrade	Underweight → Overweight	—	$32.50	$32.50	+0.0%	+9.9%	+15.5%	+25.7%	+27.2%	+27.2%
Oct 8	Bank of America	Maintains	Neutral → Neutral	—	$32.30	$26.22	-18.8%	-20.8%	-17.8%	-15.0%	-15.5%	-15.0%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

An executive appointment to external board leadership suggests confidence in management quality and may signal stability, though investors should monitor whether divided attention impacts operational focus at the primary company.

Apr 1

Data updated apr 26, 2026 9:30pm · Source: massive.com